# Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma

> **NCT06105554** · PHASE1,PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 36 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Belumosudil mesylate

## Key facts

- **NCT ID:** NCT06105554
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-30
- **Primary completion:** 2027-08-31
- **Final completion:** 2029-08-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06105554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06105554, "Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06105554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*